These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 21094906)

  • 1. Glucagon-like peptide-1 gastrointestinal regulatory role in metabolism and motility.
    Hellström PM
    Vitam Horm; 2010; 84():319-29. PubMed ID: 21094906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GLP-1: broadening the incretin concept to involve gut motility.
    Hellström PM
    Regul Pept; 2009 Aug; 156(1-3):9-12. PubMed ID: 19362109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GLP-1 playing the role of a gut regulatory compound.
    Hellström PM
    Acta Physiol (Oxf); 2011 Jan; 201(1):151-6. PubMed ID: 20518750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New physiological effects of the incretin hormones GLP-1 and GIP.
    Asmar M
    Dan Med Bull; 2011 Feb; 58(2):B4248. PubMed ID: 21299928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extrapancreatic effects of GIP and GLP-1.
    Vella A; Rizza RA
    Horm Metab Res; 2004; 36(11-12):830-6. PubMed ID: 15655715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential effects of subcutaneous GLP-1 on gastric emptying, antroduodenal motility, and pancreatic function in men.
    Schirra J; Kuwert P; Wank U; Leicht P; Arnold R; Göke B; Katschinski M
    Proc Assoc Am Physicians; 1997 Jan; 109(1):84-97. PubMed ID: 9010920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The incretin hormones GIP and GLP-1 in diabetic rats: effects on insulin secretion and small bowel motility.
    Edholm T; Cejvan K; Abdel-Halim SM; Efendic S; Schmidt PT; Hellström PM
    Neurogastroenterol Motil; 2009 Mar; 21(3):313-21. PubMed ID: 19126188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GLP-1 suppresses gastrointestinal motility and inhibits the migrating motor complex in healthy subjects and patients with irritable bowel syndrome.
    Hellström PM; Näslund E; Edholm T; Schmidt PT; Kristensen J; Theodorsson E; Holst JJ; Efendic S
    Neurogastroenterol Motil; 2008 Jun; 20(6):649-59. PubMed ID: 18298441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Actions of prolonged ghrelin infusion on gastrointestinal transit and glucose homeostasis in humans.
    Falkén Y; Hellström PM; Sanger GJ; Dewit O; Dukes G; Grybäck P; Holst JJ; Näslund E
    Neurogastroenterol Motil; 2010 Jun; 22(6):e192-200. PubMed ID: 20100281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for type 2-diabetes.
    Nauck MA; Holst JJ; Willms B; Schmiegel W
    Exp Clin Endocrinol Diabetes; 1997; 105(4):187-95. PubMed ID: 9285204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exaggerated secretion of glucagon-like peptide-1 (GLP-1) could cause reactive hypoglycaemia.
    Toft-Nielsen M; Madsbad S; Holst JJ
    Diabetologia; 1998 Oct; 41(10):1180-6. PubMed ID: 9794105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans.
    Meier JJ; Gethmann A; Nauck MA; Götze O; Schmitz F; Deacon CF; Gallwitz B; Schmidt WE; Holst JJ
    Am J Physiol Endocrinol Metab; 2006 Jun; 290(6):E1118-23. PubMed ID: 16403774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The physiological role of GLP-1 in human: incretin, ileal brake or more?
    Schirra J; Göke B
    Regul Pept; 2005 Jun; 128(2):109-15. PubMed ID: 15780430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The biology of incretin hormones.
    Drucker DJ
    Cell Metab; 2006 Mar; 3(3):153-65. PubMed ID: 16517403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glycaemic effects of incretins in Type 1 diabetes mellitus: a concise review, with emphasis on studies in humans.
    Dupre J
    Regul Pept; 2005 Jun; 128(2):149-57. PubMed ID: 15780434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Analogs of glucagon-like peptide-1 (GLP-1): an old concept as a new treatment of patients with diabetes mellitus type 2].
    Diamant M; Bunck MC; Heine RJ
    Ned Tijdschr Geneeskd; 2004 Sep; 148(39):1912-7. PubMed ID: 15495988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The entero-insular axis in type 2 diabetes--incretins as therapeutic agents.
    Creutzfeldt W
    Exp Clin Endocrinol Diabetes; 2001; 109 Suppl 2():S288-303. PubMed ID: 11460578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incretins and other peptides in the treatment of diabetes.
    Todd JF; Bloom SR
    Diabet Med; 2007 Mar; 24(3):223-32. PubMed ID: 17263764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initially more rapid small intestinal glucose delivery increases plasma insulin, GIP, and GLP-1 but does not improve overall glycemia in healthy subjects.
    Chaikomin R; Doran S; Jones KL; Feinle-Bisset C; O'Donovan D; Rayner CK; Horowitz M
    Am J Physiol Endocrinol Metab; 2005 Sep; 289(3):E504-7. PubMed ID: 15886226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus.
    Freeman JS
    Cleve Clin J Med; 2009 Dec; 76 Suppl 5():S12-9. PubMed ID: 19952298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.